title: [Results of retinalamine use in the treatment of tuberculous chorioretinitis].
abstract: The efficiency of the peptide bioregulator retinalamine in the complex treatment of patients with tuberculous chorioretinitis was studied. Ninety-seven patients (69 females and 28 males) with inactive tuberculous chorioretinitis (132 eyes) were followed up. According to the treatment option, the patients were divided into 2 groups: a study group and a control one. Parabulbar injections of retinalamine were used in the study group. The conventional treatment using parabulbar injections of emoxipine (an agent from the group of synthetic antioxidants) was performed in the control group. The results of treatment were assessed by visual acuity, the number of pathological scotomas in the field of vision and the findings of electrophysiological investigations (EPI). Analysis of the results of conventional versus peptide bioregulator therapy used in patients with inactive tuberculous chorioretinitis showed the advantages of retinalamine. This manifested itself as increased visual acuity in 66.3% of the patients receiving retinalamine while in the emoxipine-treated patients, visual acuity increased only in 20% of cases. In the patients taking retinalamine, the positive changes in the field of vision were statistically significant in the number of normal test objects, relative and absolute scotomas while in the emoxipine group, only the reduction in the number of absolute scotomas was significant. The values of EPI suggest that the peptide bioregulator is more effective in enhancing the functional activity of retinal neurons than the synthetic antioxidant.
authors.forename: T E
authors.initials: TE
authors.lastname: Aleksandrova
authors.forename: E I
authors.initials: EI
authors.lastname: Aleksandrov
mesh_terms: D000328:Adult; D000368:Aged; D002825:Chorioretinitis / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D009915:Orbit; D010455:Peptides / Q000008:administration & dosage*; D016896:Treatment Outcome; D014392:Tuberculosis, Ocular / Q000188:drug therapy* / Q000382:microbiology; D014792:Visual Acuity
chemical_list: D010455:Peptides; C503555:retinalamin